Logo image of ADTX

ADITXT INC (ADTX) Stock Fundamental Analysis

NASDAQ:ADTX - Nasdaq - US0070258027 - Common Stock - Currency: USD

1.16  -0.05 (-4.13%)

After market: 1.1995 +0.04 (+3.41%)

Fundamental Rating

1

Taking everything into account, ADTX scores 1 out of 10 in our fundamental rating. ADTX was compared to 556 industry peers in the Biotechnology industry. Both the profitability and financial health of ADTX have multiple concerns. ADTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADTX has reported negative net income.
In the past year ADTX has reported a negative cash flow from operations.
In the past 5 years ADTX always reported negative net income.
ADTX had a negative operating cash flow in each of the past 5 years.
ADTX Yearly Net Income VS EBIT VS OCF VS FCFADTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of ADTX (-100.36%) is worse than 76.16% of its industry peers.
The Return On Equity of ADTX (-188.88%) is worse than 66.31% of its industry peers.
Industry RankSector Rank
ROA -100.36%
ROE -188.88%
ROIC N/A
ROA(3y)-152.11%
ROA(5y)-160.9%
ROE(3y)-396.44%
ROE(5y)-345.59%
ROIC(3y)N/A
ROIC(5y)N/A
ADTX Yearly ROA, ROE, ROICADTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

ADTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADTX Yearly Profit, Operating, Gross MarginsADTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

ADTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADTX has more shares outstanding
Compared to 5 years ago, ADTX has more shares outstanding
The debt/assets ratio for ADTX has been reduced compared to a year ago.
ADTX Yearly Shares OutstandingADTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
ADTX Yearly Total Debt VS Total AssetsADTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -10.53, we must say that ADTX is in the distress zone and has some risk of bankruptcy.
ADTX has a Altman-Z score of -10.53. This is in the lower half of the industry: ADTX underperforms 74.19% of its industry peers.
ADTX has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ADTX (0.18) is worse than 69.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -10.53
ROIC/WACCN/A
WACC10.34%
ADTX Yearly LT Debt VS Equity VS FCFADTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.08 indicates that ADTX may have some problems paying its short term obligations.
ADTX's Current ratio of 0.08 is on the low side compared to the rest of the industry. ADTX is outperformed by 97.31% of its industry peers.
ADTX has a Quick Ratio of 0.08. This is a bad value and indicates that ADTX is not financially healthy enough and could expect problems in meeting its short term obligations.
ADTX has a worse Quick ratio (0.08) than 97.13% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
ADTX Yearly Current Assets VS Current LiabilitesADTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.21% over the past year.
The Revenue for ADTX has decreased by -89.04% in the past year. This is quite bad
The Revenue has been growing slightly by 6.80% on average over the past years.
EPS 1Y (TTM)93.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
Revenue 1Y (TTM)-89.04%
Revenue growth 3Y6.8%
Revenue growth 5YN/A
Sales Q2Q%-98.75%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2096.63%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1584.79%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADTX Yearly Revenue VS EstimatesADTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 5M 10M 15M 20M
ADTX Yearly EPS VS EstimatesADTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -10M -20M -30M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADTX. In the last year negative earnings were reported.
Also next year ADTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADTX Price Earnings VS Forward Price EarningsADTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADTX Per share dataADTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADITXT INC

NASDAQ:ADTX (7/18/2025, 8:00:00 PM)

After market: 1.1995 +0.04 (+3.41%)

1.16

-0.05 (-4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19
Earnings (Next)08-18 2025-08-18
Inst Owners4.05%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap2.82M
Analysts80
Price TargetN/A
Short Float %9.34%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 50.88
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-69980.54
EYN/A
EPS(NY)-252.96
Fwd EYN/A
FCF(TTM)-9.27
FCFYN/A
OCF(TTM)-9.27
OCFYN/A
SpS0.02
BVpS6.83
TBVpS6.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.36%
ROE -188.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-152.11%
ROA(5y)-160.9%
ROE(3y)-396.44%
ROE(5y)-345.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -10.53
F-Score3
WACC10.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
EPS Next Y-2096.63%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-89.04%
Revenue growth 3Y6.8%
Revenue growth 5YN/A
Sales Q2Q%-98.75%
Revenue Next Year1584.79%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.5%
OCF growth 3YN/A
OCF growth 5YN/A